A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

The primary objective of this study is to determine whether the administration of tanezumab, an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients receiving background non-NSAID therapy.

开始日期2020-04-30

申办/合作机构

The General Hospital Corp.

[+1]

PER-069-15

/ Recruiting临床3期

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG- TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE

开始日期2016-04-01

申办/合作机构-

NCT02709486

/ Completed临床3期

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE

Tanezumab is a monoclonal antibody that binds to and inhibits the actions of nerve growth factor (NGF). The Nerve Growth Factor Inhibitor (NGFI) class may offer an important breakthrough in the treatment of chronic pain and is under clinical investigation for the treatment of pain associated with osteoarthritis or other chronic pain conditions.
The primary objective of this study is to demonstrate superior efficacy of tanezumab 5 mg and 2.5 mg administered subcutaneously (SC) every 8 weeks versus placebo at Week 24 in subjects with osteoarthritis of the knee or hip. The 2.5 mg dose was shown to provide efficacy benefits with a favorable safety profile when administered intravenously in previous Phase 3 clinical trials. The 5 mg dose is expected to provide added efficacy benefit over the 2.5 mg dose based on data from previous studies.

开始日期2016-03-02

申办/合作机构

Pfizer Inc.

[+1]

100 项与 Tanezumab 相关的临床结果

登录后查看更多信息

100 项与 Tanezumab 相关的转化医学

登录后查看更多信息

100 项与 Tanezumab 相关的专利（医药）

登录后查看更多信息

134

项与 Tanezumab 相关的文献（医药）

2025-09-01·CPT-Pharmacometrics & Systems Pharmacology

Incorporating Multiple Imputation Into Tanezumab Dose–Response Modeling of WOMAC Pain CFB Across Six Randomized Placebo‐Controlled Phase 3 Trials

Article

作者: Marshall, Scott ; Boucher, Martin ; Gaitonde, Puneet

ABSTRACT:

Multiple imputation is increasingly being used to deal with missing data in clinical trials. It is a simulation approach leading to multiple analyses of a pre‐defined number of datasets. For a pre‐defined statistical model, this is relatively straightforward, but for model development as typically conducted in Pharmacometrics, it is unclear how such an approach could be implemented. This case study describes how this was addressed at the time of a regulatory submission and considers alternative approaches which could be adopted in the future.

2024-08-01·VETERINARY JOURNAL

Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs

Letter

作者: Tony Simon ; Phaedra Cole ; Adam Werts ; Douglas Reece

In their letter to the editor, Farrell et al., (2024) presented questions related to canine joint health after treatment with the anti-Nerve Growth Factor (NGF) monoclonal antibody (mAb) bedinvetmab, which was presented as a component of a non-clinical laboratory safety assessment published in Krautmann et al., (2021). Their questions appear to have stemmed from an anti-NGF mAb developed for the treatment of osteoarthritis in humans (tanezumab; FDA, 2021) which in 2021 failed to achieve marketing approval due to an unfavorable benefit: risk profile, primarily due to a syndrome called Rapidly Progressive Osteoarthritis (RPOA) which occurred more commonly in treatment groups when compared to controls. Farrell et. al. (2024) have posed questions on radiographic and histopathologic bone findings from studies included in Krautmann, et al., (2021) and communicated in the FDA's Freedom of Information summary for Librela (FDA, 2023). These findings have previously been determined to be incidental and not bedinvetmab-associated. To address the questions posed, it is important to briefly define RPOA and summarize the syndrome in humans, review why the bone/joint findings in bedinvetmab safety studies in dogs are not indicative of RPOA or an RPOA-like condition, provide an update on joint health after use of bedinvetmab since market approval (>3 years in some markets), and summarize why Zoetis, the manufacturer of Librela, has confidence in joint safety after use of bedinvetmab in dogs.

2023-12-11·The oncologist

A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis

Article

作者: Fallon, Marie ; Viktrup, Lars ; Bao, Weihang ; Agyemang, Alex ; Brown, Mark T ; Sopata, Maciej ; West, Christine R ; Dragon, Erika

Abstract:

Background:

This phase III, randomized, double-blind, placebo-controlled, parallel-group study assessed the efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy.

Methods:

Subjects were randomized (stratified by (1) tumor aggressiveness and (2) presence/absence of concomitant anticancer treatment) to placebo or tanezumab 20 mg. Treatment was administered by subcutaneous injection every 8 weeks for 24 weeks (3 doses) followed by a 24-week safety follow-up period. The primary outcome was change in daily average pain in the index bone metastasis cancer pain site (from 0 = no pain to 10 = worst possible pain) from baseline to week 8.

Results:

LS mean (SE) change in pain at week 8 was −1.25 (0.35) for placebo (n = 73) and –2.03 (0.35) for tanezumab 20 mg (n = 72). LS mean (SE) [95% CI] difference from placebo was –0.78 (0.37) [–1.52, –0.04]; P = .0381 with α = 0.0478. The number of subjects with a treatment-emergent adverse event during the treatment period was 50 (68.5%) for placebo and 53 (73.6%) for tanezumab 20 mg. The number of subjects with a prespecified joint safety event was 0 for placebo and 2 (2.8%) for tanezumab 20 mg (pathologic fracture; n = 2).

Conclusion:

Tanezumab 20 mg met the primary efficacy endpoint at week 8. Conclusions on longer-term efficacy are limited since the study was not designed to evaluate the durability of the effect beyond 8 weeks. Safety findings were consistent with adverse events expected in subjects with cancer pain due to bone metastasis and the known safety profile of tanezumab. Clinicaltrials.gov identifier: NCT02609828.

项与 Tanezumab 相关的新闻（医药）

2026-05-07

·今日头条

每半年一次！抗NGF单抗，中度骨关节炎慢性膝痛，非阿片类镇痛

对于吃止痛药伤胃、怕上瘾的中度膝骨关节炎患者，这可能是改变游戏规则的“长效镇痛针”。 “医生，我膝盖疼得走不了路，但吃布洛芬胃疼，吃阿片又怕上瘾，还有别的办法吗？” 在疼痛科门诊，这是无数骨关节炎（OA）患者的困境。他们需要长期镇痛，却受困于传统药物的副作用。现在，一类全新的药物—— 抗NGF单抗（神经生长因子抑制剂），正在为这类患者提供“第三极”选择。与每日服药不同，这类药物通过皮下注射给药，每半年仅需一次（部分药物间隔更短），即可实现持续镇痛。它不经过胃肠道，无成瘾性，是真正的非阿片类靶向镇痛药。本文将严格依据临床证据，解析其机制、药物与风险。一、什么是抗NGF单抗？为什么能“长效镇痛”？ NGF（神经生长因子）是疼痛信号传递的“放大器”。在骨关节炎中，关节内的炎症会刺激NGF水平飙升，导致疼痛阈值降低（痛觉敏化）——这就是为什么患者连轻微的走路都会感到剧痛。抗NGF单抗的作用机制：精准狙击：作为单克隆抗体，它能像“导弹”一样精准结合并中和体内的NGF。阻断信号：切断NGF与其受体（TrkA）的结合，从源头上减少疼痛信号向大脑的传递。长效原理：抗体类药物在体内代谢缓慢（半衰期长），注射一次可在血液中维持数周至数月的有效浓度，从而实现长期镇痛。关键优势：它不抑制 COX 酶（不像布洛芬伤胃），也不激动阿片受体（不像吗啡上瘾），作用机制完全独立。二、具体药物：哪些已接近临床？目前全球范围内，多款抗NGF单抗已进入III期临床或上市审批阶段。需要明确的是：严格意义上的“每半年一次”是理想化的给药间隔，不同药物研发进度和周期略有差异，以下为最接近临床应用的候选药物： 1. 塔奈珠单抗（Tanezumab）研发状态：由辉瑞/礼来研发，已完成多项III期临床，但在FDA审批中因关节安全信号受阻，目前定位为其他疗法无效后的“末线选择” 。给药频率：通常为每8周（约2个月）皮下注射一次。证据：在难治性膝/髋OA患者中，相比安慰剂，能显著改善WOMAC疼痛评分（行走痛减轻约45%-62%）。 2. 法西努单抗（Fasinumab）研发状态：由再生元/梯瓦研发，III期数据显示其对中重度OA疼痛有效，但同样面临关节安全监测。给药频率：临床研究中多为每月至每季度给药。特点：全人源化单抗，免疫原性更低。 3. 富兰尼单抗（Fulranumab）研发状态：杨森曾推进其研发，Meta分析显示其可改善OA疼痛，但研发已放缓。关于“每半年一次” ：目前公开数据中，尚无严格“半年一针”的获批药物。 “每半年一次”是媒体对长效镇痛理想的通俗概括，实际临床中多为2-3个月一次。患者需关注具体药物的说明书。三、核心优势：为什么它是“非阿片”的里程碑？对于中度OA慢性膝痛患者，抗NGF单抗的价值在于填补了巨大的治疗空白：维度抗NGF单抗（如Tanezumab）非甾体抗炎药（NSAIDs）阿片类药物镇痛机制靶向NGF，抑制痛觉敏化抑制COX，抗炎镇痛中枢μ受体激动，抑制痛觉成瘾性无无高，需严格管控胃肠道风险极低（不经口服）高（溃疡、出血）有（便秘、恶心）心血管风险未见明确关联高（尤其塞来昔布类）有（呼吸抑制）给药方式皮下注射，长效每日口服每日口服/贴剂适用人群画像：确诊为中度膝骨关节炎，疼痛评分≥4分（0-10分）。对NSAIDs 不耐受（如胃病、肾病）或疗效不足。存在阿片滥用风险，或拒绝使用阿片类药物。希望减少每日服药负担，追求长效治疗。四、不可忽视的“黑框警告”：关节破坏风险这是抗NGF单抗最受争议的一点，也是FDA审评专家投票反对其广泛使用的主要原因。 1. 快速进展性骨关节炎（RPOA）现象：部分患者在用药后，关节结构破坏加速，出现软骨快速丢失、骨坏死，甚至需要提前进行关节置换。机制：NGF本身对软骨和骨骼有营养作用。完全阻断NGF后，可能削弱了关节的自我保护机制，加上疼痛消失导致患者活动量过大（类似“无痛关节”过度使用），加速了磨损。发生率：在III期研究中，RPOA发生率约为1%-3%，显著高于安慰剂组。 2. 神经系统副作用部分患者报告出现感觉异常、麻木（周围神经病变），通常停药后可逆，但需密切监测。监管态度：目前FDA和EMA均未批准其作为OA的一线治疗。仅建议用于无其他治疗选择、且充分知情同意关节风险的患者。五、给患者的理性建议它不是“神药” ：抗NGF单抗是镇痛药，不是修复药。它只能缓解疼痛，不能逆转软骨磨损，也不能治愈骨关节炎。严格筛选：重度OA（关节间隙已消失）、拟行关节置换者、合并严重周围神经病变者禁用。用药前需拍摄X线片评估基线关节状态。中国现状：截至2026年，此类药物在中国大多处于临床研究或审批阶段，尚未广泛进入医保。患者切勿轻信“海外代购”或“黑市针剂”。基础治疗不能停：即使打了针，减重、肌力训练、物理治疗仍是OA治疗的基石。药物只是让你“不疼”，运动才能让你“走得远”。抗NGF单抗代表了慢性疼痛治疗的未来方向：靶向、长效、非成瘾。对于饱受疼痛折磨且无药可用的患者，它是一道曙光。然而，关节安全风险像一把达摩克利斯之剑，限制了它的广泛应用。行动指南：若你符合“中度膝痛、传统药无效”的特征，可咨询三甲医院疼痛科或风湿科，询问是否有相关的临床研究（临床试验）机会。若听闻“半年一针”的宣传，务必核实具体药物名称（如Tanezumab）和确切的给药间隔。在获得更长期的安全性数据前，将其视为“最后的手段”而非首选。参考文献： Tanezumab for osteoarthritis: efficacy and safety meta-analysis. J Pain Res. 2020. Schnitzer TJ, et al. Effect of Tanezumab on Joint Pain and Physical Function in Patients with Osteoarthritis. JAMA. 2019. FDA Arthritis Advisory Committee Meeting Briefing Document: Tanezumab. 2021. Fasinumab phase III data in RMD Open. 2026. （注：本文提及药物均为处方药或临床研究阶段药物，严禁自行使用；具体用药需在医生全面评估风险后决定）

2026-05-06

·BioSpace

New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain

STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that a scientific article has been published on the preclinical characterization of ACD137, the lead drug candidate in the TrkA-NAM pain project. The scientific article, titled Analgesic, anti-inflammatory and joint protective effects of ACD137, a selective negative allosteric modulator of TrkA, in models of chemotherapy-induced peripheral neuropathy and osteoarthritis , has been published online in the Scandinavian Journal of Pain and is written by Pontus Forsell, PhD and Head of Discovery & Research at AlzeCure Pharma. Co-authors are Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado Fernandez, Märta Segerdahl, Johan Sandin and Gunnar Nordvall. The article describes how the lead drug candidate in the TrkA-NAM project, Painless ACD137, was developed and characterized. Data from the preclinical studies show that the substance is highly potent and selective, with good properties for further development as a drug. ACD137 mediates its effects by blocking NGF-mediated signaling via TrkA receptors, a biological mechanism with strong genetic, preclinical and clinical validation for its role in pain. The substance has potent analgesic effects in several different preclinical pain models, both in neuropathic pain and in models of osteoarthritis-related pain. The analgesic effect of ACD137 has been shown in a comparative study to be as effective as the anti-NGF antibody Tanezumab, which has demonstrated significant and robust pain relief in several large clinical trials. Furthermore, anti-inflammatory and protective effects on the knee joint were observed, indicating a disease-modifying effect and which has great potential value in patients with osteoarthritis. "This article describes how we have worked in our TrkA-NAM program to identify the highly potent and selective TrkA-NAM compound, ACD137. The compound has potent analgesic effects in preclinical in vivo models, both in neuropathic and nociceptive pain, indicating multiple applications in pain relief. Due to the selective mechanism of action, we also expect a much better safety pro this class of compounds compared to anti-NGF antibodies," said Pontus Forsell, project leader and Head of Discovery & Research at AlzeCure Pharma. "We are very pleased and proud of the results presented in this scientific publication. There is a significant and growing interest in our TrkA-NAM program among external stakeholders, especially since the mechanism of action has not shown the side effects and addiction problems observed with opioids. In addition, the medical need is very large and growing. Today, it is estimated that over 600 million people suffer from painful osteoarthritis*," said Martin Jönsson, CEO of AlzeCure Pharma. The article is now available online via the following link: *) Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021; The Lancet, Volume 5, Issue 9, 2023 For more information, please contact Martin Jönsson, CEO Tel: +46 707 86 94 43 martin.jonsson@alzecurepharma.com About AlzeCure Pharma AB (publ) AlzeCure ® is a Swedish clinical stage biotech company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless. NeuroRestore consists of one symptomatic drug candidate where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. NeuroRestore has received an EU grant from the European Innovation Council and is being prepared for phase 2. Alzstatin focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless contains two projects: ACD440, which is a drug candidate for the treatment of neuropathic pain with positive phase 2 results and orphan drug designation from the FDA in the USA and from EMA in Europe for the rare pain disease erythromelalgia, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . Image Attachments Martin Jönsson CEO And Pontus Forsell Head Of D&R AlzeCure Pharma Attachments New scientific article published on TrkA-NAM ACD137 against osteoarthritic pain SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire

临床2期孤儿药

2026-04-15

·用药明白纸

中青年男性慢性前列腺炎常用的20种药物及作用特点

常用药物20种清单（按作用分类，类内按常用程度降序）一、改善排尿症状与盆底出口张力1. 坦索罗辛作用特点：选择性α1受体阻滞剂，松弛前列腺与膀胱颈平滑肌，改善排尿困难、尿线细、排尿等待等下尿路症状，并可能减轻疼痛相关不适[1]。2. 多沙唑嗪作用特点：α受体阻滞剂，机制与坦索罗辛同类，用于改善排尿症状与疼痛[1]。3. 特拉唑嗪作用特点：α受体阻滞剂，改善排尿症状与疼痛相关不适[1]。4. 赛洛多辛作用特点：α受体阻滞剂，用于改善CP/CPPS相关排尿症状与疼痛[1]。5. 萘哌地尔作用特点：α受体阻滞剂，用于改善排尿症状与疼痛[1]。6. 阿夫唑嗪作用特点：α受体阻滞剂，可改善CP/CPPS患者的排尿症状及疼痛[2]。7. 乌拉地尔缓释胶囊作用特点：α受体阻滞剂，可用于改善CP/CPPS患者的排尿症状及疼痛[2]。二、抗感染治疗（需严格把握适应证）8. 左氧氟沙星作用特点：氟喹诺酮类抗生素，具有较好组织渗透性，可作用于前列腺组织中的病原菌[4]。9. 环丙沙星作用特点：氟喹诺酮类抗生素，用于对敏感菌相关的感染表型治疗[1]。10. 阿奇霉素作用特点：大环内酯类抗生素，用于特定病原学线索或经验性治疗的备选方案之一[1]。11. 米诺环素作用特点：四环素类抗生素，用于特定病原学线索或经验性治疗的备选方案之一[1]。三、抗炎镇痛与炎症调控12. 非甾体抗炎药（NSAIDs，如布洛芬、塞来昔布等）作用特点：通过抑制环氧化酶发挥抗炎、镇痛作用，用于CP/CPPS相关疼痛的对症控制[1]。四、植物制剂与天然产物13. 普适泰片作用特点：花粉提取物制剂，研究提示其可抑制环氧合酶与脂氧合酶活性、降低白三烯与前列腺素合成，并可能影响雄激素代谢通路，从而发挥抗炎、抗水肿等作用[5]。14. 沙巴棕软胶囊作用特点：沙巴棕提取物制剂，研究描述其具有抗炎、抗水肿、缓解排尿症状等作用[6]。五、神经调节与心理共病管理15. 选择性5-羟色胺再摄取抑制剂（SSRIs，如氟西汀、帕罗西汀、舍曲林）作用特点：抗抑郁抗焦虑药物，可改善合并抑郁、焦虑等心境障碍患者的心理症状，并可能缓解疼痛等躯体症状[1]。16. 5-羟色胺去甲肾上腺素再摄取抑制剂（SNRIs，如度洛西汀）作用特点：抗抑郁抗焦虑药物，兼具疼痛调节作用，用于合并心境障碍或慢性疼痛表型的综合管理[1]。17. 三环类抗抑郁药（如阿米替林）作用特点：抗抑郁抗焦虑药物，可用于合并心境障碍或慢性疼痛表型的综合管理[1]。18. 普瑞巴林作用特点：钙通道调节剂，用于神经病理性疼痛表型的镇痛治疗。六、中成药19. 前列舒通胶囊作用特点：复方中成药，组方包含黄柏、赤芍、虎耳草、川芎、当归等，功能为清热利湿、活血祛瘀、消肿散结，常用于湿热瘀阻证候相关的慢性前列腺炎症状管理[5]。20. 泽桂癃爽胶囊作用特点：由皂角刺、泽兰、肉桂组成，研究描述其可发挥活血祛瘀、利水消肿、托毒杀虫、理气止痛等作用，适用于“膀胱瘀阻”病机相关的慢性前列腺炎证候[4]。合并症导向的加用药物与前沿方向伴膀胱过度活动症状（尿急、尿频、夜尿）且无下尿路梗阻 M受体阻滞剂：如索利那新、托特罗定，可用于伴OAB表现且无尿路梗阻者[1]；专家共识指出M受体阻滞剂与β3受体激动剂单药或联合可改善OAB相关排尿症状并降低相关评分[2]。系统综述提示抗胆碱能药对症状改善可能无效，证据质量为中等到高质量[3]。 β3受体激动剂：如米拉贝隆，可用于伴OAB且无梗阻者[1]；专家共识将其与M受体阻滞剂并列为可选方案[2]。合并性功能障碍或疼痛与性功能相互影响 5型磷酸二酯酶抑制剂：如他达拉非、西地那非，专家共识指出可用于合并高血压与下尿路症状的男性患者[2]；系统综述提示磷酸二酯酶抑制剂可能改善症状且不良事件未见增加，但证据质量偏低[3]。达泊西汀：专家共识指出其治疗慢性前列腺炎合并早泄有效[2]；综述亦指出5-羟色胺再摄取抑制剂可用于合并早泄的表型管理[8]。难治性疼痛的介入与生物制剂探索前列腺内肉毒毒素A注射：系统综述提示其可能带来较大幅度症状改善，但存在血尿等操作相关不良事件，且证据质量偏低；而盆底肌注射可能未显示同等效果[3]。目前更适合在严格筛选的难治病例、充分告知证据不确定性后开展。 Tanezumab等新型镇痛靶点药物：系统综述提示其可能无效，证据质量偏低[3]，仍属探索阶段。全部引用慢性前列腺炎/慢性盆腔疼痛综合征诊疗指南高原地区慢性前列腺炎/慢性盆腔疼痛综合征临床管理专家共识 Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. 泽桂癃爽胶囊联合左氧氟沙星治疗慢性前列腺炎的临床研究前列舒通胶囊联合普适泰片治疗慢性前列腺炎的临床研究针灸联合沙巴棕软胶囊治疗慢性前列腺炎慢性骨盆疼痛综合征疗效研究前列舒通胶囊治疗慢性前列腺炎湿热瘀阻证的临床综合评价中西医结合治疗慢性前列腺炎合并早泄研究进展

100 项与 Tanezumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09387	Tanezumab	-	DB12335

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨关节炎	申请上市	欧盟	Pfizer Europe MA EEIG	-
骨转移癌	临床3期	中国	Pfizer Inc.	2015-10-28
骨转移癌	临床3期	日本	晖致制药（大连）有限公司	2015-10-28
骨转移癌	临床3期	日本	Pfizer Inc.	2015-10-28
骨转移癌	临床3期	阿根廷	Pfizer Inc.	2015-10-28
骨转移癌	临床3期	阿根廷	晖致制药（大连）有限公司	2015-10-28
骨转移癌	临床3期	澳大利亚	Pfizer Inc.	2015-10-28
骨转移癌	临床3期	澳大利亚	晖致制药（大连）有限公司	2015-10-28
骨转移癌	临床3期	奥地利	晖致制药（大连）有限公司	2015-10-28
骨转移癌	临床3期	奥地利	Pfizer Inc.	2015-10-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02528188 \| NCT02709486 \| NCT02697773 (Pubmed \| Osteoarthritis Cartilage)	临床3期	骨关节炎	4,541	Tanezumab 2.5mg	簾鹹糧壓淵製膚蓋憲膚(憲襯壓膚顧衊淵窪製餘) = 觸鑰襯醖廠簾夢鏇鑰壓窪夢窪簾壓觸蓋鹽遞願 (淵範顧衊淵餘鹹選膚糧 )	积极	2023-12-01
				Tanezumab 5mg	簾鹹糧壓淵製膚蓋憲膚(憲襯壓膚顧衊淵窪製餘) = 網願壓築製壓鹹鹹積壓窪夢窪簾壓觸蓋鹽遞願 (淵範顧衊淵餘鹹選膚糧 )
NCT02528188 \| NCT02709486 \| NCT02697773 (pivotal phase III interventional studies, Pubmed \| CPT Pharmacometrics Syst Pharmacol)	临床3期	nerve growth factor (NGF)	2,992	Tanezumab 2.5 mg	蓋鹽鬱襯鹽鬱構獵壓壓(鏇憲鏇簾願範膚觸選願) = 鏇憲憲願獵簾構鏇壓齋積壓繭範醖餘衊膚製齋 (鑰構鬱範鑰襯餘夢網鹹 )	积极	2023-09-01
NCT02609828 (CTgov)	临床3期	癌症疼痛 \| 骨转移癌	156	placebo+tanezumab (Placebo)	鏇選觸膚願餘壓鏇糧鹹(構築膚夢觸獵繭鏇醖衊) = 夢積簾膚餘餘獵衊鬱選獵艱觸憲餘繭壓網鹹願 (繭衊範餘願衊顧醖窪壓, 0.35) 更多	-	2023-01-20
				Tanezumab (Tanezumab 10 mg)	鏇選觸膚願餘壓鏇糧鹹(構築膚夢觸獵繭鏇醖衊) = 繭選選鬱遞膚齋壓選繭獵艱觸憲餘繭壓網鹹願 (繭衊範餘願衊顧醖窪壓, NA) 更多
NCT02528188 \| NCT02709486 \| NCT02697773 (NCT02528188 \| NCT02709486 \| NCT02697773, Pubmed \| Adv Ther)	临床3期	骨关节炎	-	NSAIDs	餘獵網齋醖糧鏇鬱鏇積(窪鏇範鹹繭繭製夢網窪) = 願鹹廠構構鏇製選遞網鹹觸襯淵齋糧鏇簾襯遞 (鏇範鹽構遞獵簾築憲醖 )	-	2023-01-01
				Tanezumab 2.5 mg	餘獵網齋醖糧鏇鬱鏇積(窪鏇範鹹繭繭製夢網窪) = 齋淵選繭觸淵網鏇範鬱鹹觸襯淵齋糧鏇簾襯遞 (鏇範鹽構遞獵簾築憲醖 )
NCT02528188 \| NCT02709486 \| NCT02697773 (Phase 3 trials of tanezumab, Pubmed \| Osteoarthr Imaging)	临床3期	骨关节炎	-	Tanezumab	顧遞窪淵齋製膚艱鏇觸(鏇壓糧鏇繭憲鏇艱艱選) = 鏇淵壓蓋壓壓獵鬱鹹獵糧壓願獵築選願構襯鏇 (鹽壓簾艱構鏇餘鑰醖夢 )	-	2022-09-01
NCT02528188 \| NCT02709486 \| NCT02697773 (Pubmed)	临床3期	髋关节炎 \| 膝关节炎	-	Tanezumab	遞糧獵構淵構憲構製窪(觸鹹鬱壓襯遞構糧觸繭) = 衊網鹽餘簾膚繭繭顧夢簾襯簾築範範簾網築觸 (齋選廠衊觸餘鹹糧夢網 )	-	2022-03-01
NCT02528188 (Pubmed \| J Neurol Sci)	临床3期	骨关节炎	3,021	Tanezumab 2.5mg	淵鑰獵醖範觸鏇網憲齋(膚鏇網襯構簾鹽鏇築選) = 膚範鹽餘壓網鑰壓餘顧膚築築範網鬱鬱衊獵遞 (鹹餘膚範齋顧鑰鏇築廠 ) 更多	积极	2022-02-14
				Tanezumab 5mg	淵鑰獵醖範觸鏇網憲齋(膚鏇網襯構簾鹽鏇築選) = 選壓顧淵觸遞憲夢簾餘膚築築範網鬱鬱衊獵遞 (鹹餘膚範齋顧鑰鏇築廠 ) 更多
NCT02725411 (Pubmed)	临床3期	腰痛	277	Tanezumab 5 mg	窪膚鏇遞遞蓋鑰製襯夢(製積膚繭選衊餘鏇鏇願) = 壓簾廠積遞鏇積蓋網膚築鬱顧顧艱鏇構鹹艱網 (鹹製遞鑰遞製糧齋觸齋 ) 更多	-	2021-11-17
				Tanezumab 10 mg	窪膚鏇遞遞蓋鑰製襯夢(製積膚繭選衊餘鏇鏇願) = 糧齋願齋鏇築醖廠膚觸築鬱顧顧艱鏇構鹹艱網 (鹹製遞鑰遞製糧齋觸齋 ) 更多
NCT02528188 \| NCT02709486 \| NCT02697773 (ACR2021)	临床3期	骨关节炎	4,541	Placebo	鏇艱衊願廠壓糧糧製鑰(窪積積憲範願構壓鏇遞) = 鹽蓋鬱夢簾鑰壓餘獵齋製醖廠壓壓鏇願網淵顧 (膚範顧築憲遞繭糧簾窪 )	不佳	2021-11-07
				Tanezumab 2.5 mg	鏇艱衊願廠壓糧糧製鑰(窪積積憲範願構壓鏇遞) = 簾選鹽鹹艱顧衊鹹獵繭製醖廠壓壓鏇願網淵顧 (膚範顧築憲遞繭糧簾窪 )
NCT02528188 (ACR2021)	临床3期	关节游离体	-	Tanezumab 2.5mg	簾襯憲構獵糧範築鑰鹽(醖獵餘艱構醖顧積鑰鬱) = 鹹壓簾艱壓醖鹹築網築餘憲鬱網範構範糧範憲 (繭觸願鹽憲簾製蓋積窪 ) 更多	积极	2021-11-07
				Tanezumab 5mg	簾襯憲構獵糧範築鑰鹽(醖獵餘艱構醖顧積鑰鬱) = 襯積衊顧顧製築齋衊糧餘憲鬱網範構範糧範憲 (繭觸願鹽憲簾製蓋積窪 ) 更多